Healthcare companies dealing with rare diseases are significant for investors. These companies have a direct and favorable regulatory pathway for drug approval, and once approved the fear of generics or competition becomes less. Synageva Biopharma (NASDAQ:GEVA) is a good example of this. Its lead pipeline candidate, Sebelipase Alfa, is in Phase III development for lysosomal acid lipase, or LAL, deficiency. I see Sebelipase Alfa as a low risk development applicant with a $600 million market potential. Sebelipase Alfa, along with a broad pipeline of other applicants for rare diseases, makes Synageva an attractive investment for long-term growth.
Rare and ultra-rare diseases like Lysosomal Storage Disorders, or LSDs, Mucopolysaccharidosis, or MPS, and TTR-mediated amyloidosis, or ATTR, generally have...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|